Acquisition-minded Boston Scientific plans to add another companyto its portfolio. The Natick, MA, catheter developer last monthannounced an agreement to acquire Target Therapeutics, a Fremont,CA, company that develops catheters and other devices used
Acquisition-minded Boston Scientific plans to add another companyto its portfolio. The Natick, MA, catheter developer last monthannounced an agreement to acquire Target Therapeutics, a Fremont,CA, company that develops catheters and other devices used inminimally invasive procedures to treat neurovascular diseases.Target also has a strong position in interventional neuroradiology.
Boston Scientific plans to trade 1.07 shares of its stock foreach Target share in a stock swap valued at $1.1 billion. Targetlast week posted revenues for its third quarter of fiscal 1997(end-December) of $23.9 million, compared with $19 million inthe same period of fiscal 1996. The company had third-quarternet income of $3.8 million, compared with $3.6 million in thesame period a year ago. The acquisition is expected to close inthe second quarter.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.